Today: 20 December 2025
Subscribe
Browse Category

NYSE:KVUE News 14 October 2025 - 19 December 2025

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Inc. (NYSE: KVUE) — the consumer-health company behind Tylenol, Band-Aid, Listerine, Aveeno, and Neutrogena — is trading in a very particular kind of market right now: not just “up or down,” but “how likely is the Kimberly-Clark deal to
19 December 2025
 ·  ·  ·  ·  ·  · 
Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Inc. (NYSE: KVUE)—the consumer health company behind brands such as Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno—is trading in a market that feels less like “buy-and-hold fundamentals” and more like “event-driven probability.” The reason: Kimberly-Clark’s planned acquisition of Kenvue, a
15 December 2025
 ·  ·  ·  ·  ·  · 
Kenvue (KVUE) Stock Today: Dividend Payout, Insider Buying and Kimberly-Clark Deal in Focus – November 26, 2025

Kenvue (KVUE) Stock Today: Dividend Payout, Insider Buying and Kimberly-Clark Deal in Focus – November 26, 2025

Kenvue Inc. (NYSE: KVUE) — the Johnson & Johnson consumer-health spin‑off behind Tylenol, Listerine and Neutrogena — is back in the spotlight on Wednesday, November 26, 2025, as the stock trades higher on dividend payday, fresh insider and hedge‑fund buying
26 November 2025
 ·  ·  ·  ·  ·  · 
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

At a glance — price & drivers (midday, Nov. 18, 2025) Market action and context KVUE softened today after Monday’s developments in federal litigation tied to claims that prenatal acetaminophen use raises autism risk. A three‑judge appeals panel questioned the
18 November 2025
 ·  ·  ·  ·  ·  · 
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

NJ Stock: What to Know Before the Bell on November 10, 2025 (Fresh FDA Wins, Dividend Date, and Legal Overhang)

Dateline: Monday, November 10, 2025 — pre‑market Johnson & Johnson (NYSE: JNJ) starts the new week with momentum from multiple drug approvals, a firm dividend timetable, and a still‑active litigation backdrop. Here’s a concise, investor‑focused briefing on the key developments
9 November 2025
 ·  ·  ·  ·  ·  ·  · 
P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

PG Stock Today: What to Know Before the Bell on November 10, 2025 (Earnings, Dividend, Tariffs, and Sector M&A)

Summary (read this first)• PG closed Friday, November 7 at $146.98, sitting near the low end of its 52‑week range ($144.46–$180.43). Market cap is about $343B. StockAnalysis+1• P&G’s latest quarter (reported Oct. 24) delivered net sales of $22.4B (+3% y/y),
9 November 2025
 ·  ·  ·  ·  ·  ·  · 
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Company Overview & History Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” (knowledge) and “vue” (view), reflecting a vision of insight-driven care en.wikipedia.org. As a spin-off,
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company,
14 October 2025
 ·  ·  ·  ·  ·  · 
Go toTop